Actoverco Pharmaceutical Group officially unveiled its medications Tirzacto and Semacto during a ceremony held in conjunction with National Physicians’ Day, honoring three prominent figures in Iran’s medical community for their contributions to endocrinology, metabolism, and internal medicine.
According to the Public Relations Department of Actoverco Pharmaceutical Group, Tirzacto and Semacto are the brand names of Tirzepatide and Semaglutide, respectively, manufactured by the Group and supplied in injectable pen formats.
Tirzacto contains Tirzepatide, a medication that acts simultaneously on GIP and GLP-1 receptors. By enhancing glucose-dependent insulin secretion, reducing appetite, increasing feelings of fullness, and delaying gastric emptying, it plays a role in blood glucose control and weight reduction.
Tirzepatide was first introduced by pharmaceutical company Eli Lilly under the brand name Mounjaro. Actoverco’s Tirzacto is available in prefilled injection pens in six strengths: 2.5, 5, 7.5, 10, 12.5, and 15 mg.
Semacto contains Semaglutide, a GLP-1 receptor agonist. By acting on pathways involved in appetite regulation and food intake, as well as enhancing glucose-dependent insulin secretion, it is used for blood glucose control and weight management.
Semaglutide was previously introduced to the market under the brand name Ozempic. Actoverco’s Semacto is supplied in adjustable, prefilled pens for subcutaneous administration in 0.25/0.5, 1, and 2 mg strengths.
Honoring Three Distinguished Medical Professionals
During the ceremony, held to mark National Physicians’ Day, Nahaleh Naraghi delivered remarks, followed by a tribute to three distinguished members of Iran’s medical community.
The honorees were:
- Dr. Manouchehr Khan Nakhjavani, Professor of Endocrinology and Metabolism at the School of Medicine, Tehran University of Medical Sciences, specializing in adult endocrinology and metabolism.
- Dr. Iraj Khosronia, Professor at Shahid Beheshti University of Medical Sciences and Specialist in Internal Medicine and Gastroenterology.
- Dr. Alireza Estegamati, Professor of Endocrinology and Metabolism, Subspecialist in Endocrinology and Metabolism, and Dean of the School of Medicine at Tehran University of Medical Sciences.
Weight Innovation Network (WIN) Event
Another key part of the ceremony was the Weight Innovation Network (WIN) event, which featured scientific presentations by leading medical specialists on metabolic disorders, diabetes, obesity, and associated complications.
Dr. Saeed Kalbasi, Associate Professor of Endocrinology and Metabolism at Shahid Beheshti University of Medical Sciences and President of the Iranian Diabetes Association, delivered a presentation entitled “Early Metabolic Dysfunction: Polycystic Ovary Syndrome Accompanied by Insulin Resistance and Obesity-Related Functional Impairment.”
Dr. Reza Ghanavati, Cardiologist, addressed the topic of “Type 2 Diabetes Accompanied by Atherosclerotic Cardiovascular Disease and the Obesity-Related Heart Failure Phenotype.”
Dr. Mohammadreza Mohajeri-Tehrani, Professor of Endocrinology and Metabolism at Tehran University of Medical Sciences, also presented on “Metabolic Liver Disease and Its Association with Cardiovascular Disease Risk and the Progression of Cardiorenal Disease in Patients with Diabetes.”
The ceremony was organized to introduce Actoverco’s expanding pharmaceutical capabilities in diabetes care and weight management, while highlighting the important role of the medical community in improving health outcomes and managing metabolic diseases.
